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Homozygous mutations of the glucocerebrosidase gene (GBA) cause Gaucher disease (GD), and hetero-
zygous mutations of GBA are a major risk factor for Parkinson’s disease (PD). This study examined the
impact of GBA mutations on the longitudinal clinical course of PD patients by retrospective cohort design.
GBA-coding regions were fully sequenced in 215 PD patients and GD-associated GBA mutations were
identiﬁed in 19 (8.8%) PD patients. In a retrospective cohort study, time to develop dementia, psychosis,
wearing-off, and dyskinesia were examined. Survival time analysis followed a maximum 12-year obser-
vation (median 6.0 years), revealing that PD patients with GD-associated mutations developed dementia
and psychosis signiﬁcantly earlier than those without mutations (p < 0.001 and p ¼ 0.017, respectively).
Adjusted hazard ratios of GBA mutations were 8.3 for dementia (p < 0.001) and 3.1 for psychosis (p ¼
0.002). No statistically signiﬁcant differences were observed for wearing-off and dyskinesia between the
groups. N-isopropyl-p[123I] iodoamphetamine single-photon emission tomography pixel-by-pixel analysis
revealed that regional cerebral blood ﬂow was reduced in the bilateral parietal cortex, including the
precuneus of GD-associated mutant PD patients, compared with matched PD controls without mutations.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Homozygous and compound heterozygous mutations in GBA
encoding glucocerebrosidase lead to Gaucher disease (GD). A link
between heterozygous GBAmutations and Parkinson’s disease (PD)
has been suggested (Bembi et al., 2003; Goker-Alpan et al., 2004;
Halperin et al., 2006; Machaczka et al., 1999; Neudorfer et al., 1996;
Tayebi et al., 2001, 2003). In 2009, a 16-center worldwide analysis of
GBA revealed that heterozygous GBA mutation carriers have a
strong risk of PD (Sidransky et al., 2009).
In addition, heterozygote GBAmutations not only carry a risk for
PD development but also the possibility of some risk burden on the
progression of PD clinical course. In cross-sectional analyses of GBA
mutations in PD patients, earlier disease onset, increased cognitiver, Department of Neurology,
yoku, Kyoto 616-8255, Japan.
a).
Inc. This is an open access article uimpairment, a greater family history of PD, and more frequent pain
were reported in patients with mutations, compared with no mu-
tations (Chahine et al., 2013; Clark et al., 2007; Gan-Or et al., 2008;
Kresojevic et al., 2015; Lwin et al., 2004; Malec-Litwinowicz et al.,
2014; Mitsui et al., 2009; Neumann et al., 2009; Nichols et al., 2009;
Seto-Salvia et al., 2012; Sidransky et al., 2009; Swan and Saunders-
Pullman, 2013; Wang et al., 2012). Recently, a few prospective
studies have investigated clinical features of PD with GBA and
showed a more rapid progression of motor impairment and
cognitive decline in GBAmutation cases than in PD controls (Beavan
et al., 2015; Brockmann et al., 2015; Winder-Rhodes et al., 2013).
However, in terms of motor complications such as wearing-off and
dyskinesia, no studies exist in the longitudinal course of PD with
GBA mutations.
Here, we conducted a multicenter retrospective cohort analysis,
and the data were investigated by survival time analysis to show
the impact of GBA mutations on PD clinical course. We also inves-
tigated regional cerebral blood ﬂow (rCBF) and cardiac sympathetic
nerve degeneration of subjects with GBAmutations, comparedwith
matched PD controls.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study design
At ﬁrst the prevalence of GBAmutations was compared between
PD patients and healthy controls and the relative risk of PD devel-
opment according to GBA mutations were estimated. Then, PD
features were compared between patients with GBAmutations and
those without mutations. Finally, a retrospective cohort analysis
was adopted to investigate the clinical course of PD according toGBA
mutations. In addition, the cardiac sympathetic denervation and
rCBF reduction were analyzed by 123I-metaiodobenzylguanidine
(MIBG) myocardial scintigraphy and N-isopropyl-p[123I] iodoam-
phetamine single-photon emission tomography images, respec-
tively, and the data of subjects with GBAmutations were compared
to sex-, age (5 years)-, and duration (5 years)-matched subjects
without mutations.
2.2. Sample size calculation
In a previous study on the incidence of dementia in PD
patients during a 20-year follow-up, 48% of the patients
developed dementia in 15 years and 83% of the survivors had
dementia within 20 years (Hely et al., 2008). Based on these ﬁg-
ures, we assumed that the cumulative incidence of dementia
(according to the criteria of the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition; DSM IV) was 30% in PD pa-
tients without GBA mutations within 12 years from disease onset;
and that it would be twice that in PD patients with mutations,
though there was no longitudinal report of the incidence of
dementia in PD patients with GBA mutations. The prevalence of
GD-associated GBA heterozygote mutations in Japanese patients
with PD has been reported as 9.4% (Mitsui et al., 2009). Therefore,
the sample size for a log-rank test was calculated as 215 partici-
pants on condition that a was 0.05 (bilateral) and that the power
was 0.9.
2.3. Study participants
From April 2010 to May 2014, we enrolled 224 PD patients in 3
neurological centers in the Kansai region of Japan. A PD diagnosis
was made according to steps 1 and 2 of the United Kingdom
Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria,
except for the criterion of >1affected relative in step 2 (Gibb and
Lees, 1988). Dementia with Lewy bodies (DLB) was diagnosed
according to criteria for the clinical diagnosis of DLBwith the 1-year
rule (McKeith et al., 2005) and was excluded from subjects. In
addition, 1.5-Tesla brain magnetic resonance imaging (MRI) was
performed in all patients, excluding those with MRI ﬁndings
compatible withmultiple system atrophy or vascular parkinsonism.
To calculate the risk ratios of PD by GBAmutations, healthy spouses
who were not members of the extended family of the study
patients, with no family history of PD or GD and who provided
written informed consent, were enrolled as controls.
2.4. Ethics
The study was designed and performed according to the Ethical
Guidelines for Clinical Studies from the Ministry of Health, Labor,
and Welfare of Japan. The protocol was approved by the ethics
committees of the participating institutions. All eligible individuals
were informed of the purpose and methods of the study, and all
provided written consent. All the individual genomic testing for
GBA was done strictly according to research protocol, without re-
turn of results.2.5. Sequencing of the GBA
Genomic DNA was extracted from peripheral blood leukocytes
or buccalmucosal swabs using standard procedures. To amplifyGBA
by polymerase chain reaction, we used 3 primer pairs described in
previous reports that were designed to selectively amplify GBA and
not its pseudogene (Koprivica et al., 2000; Mitsui et al., 2009). The
polymerase chain reaction products were subjected to direct
nucleotide sequence analyses for the GBA-coding sequences and
ﬂanking splice sites using the primers selected according to a pre-
vious report (Mitsui et al., 2009) with a DNA analyzer (ABI3730xl;
Life Technologies, Grand Island, NY, USA). The identiﬁed GBA mu-
tations were used to search against reported GD mutations with
HGMD professional (Biobase, Wolfenbuettel, Germany) to distin-
guish GD-associated mutations from other unreported mutations.
The allele names refer to the processed protein (excluding the 39-
residue signal peptide).
2.6. Data collection
Data were collected by the investigators (Tomoko Oeda,
Atsushi Umemura, Satoshi Tomita, Masayuki Kohsaka, Kwiyoung
Park, Kimiko Inoue, Harutoshi Fujimura, Hiroshi Hasegawa, Hir-
oshi Sugiyama, and Hideyuki Sawada) who all are neurologists
qualiﬁed by the Japanese Society of Neurology. They ﬁlled in the
forms of case cards designed for the study according to the pro-
tocol. The data of modiﬁed Hoehn and Yahr stage (on period), the
Uniﬁed Parkinson’s Disease Rating Scale part 3 (on period), and
the Mini-Mental State Examination were recorded at study
enrollment. Development of wearing-off, dyskinesias, orthostatic
hypotension symptoms, and dementia were collected by review-
ing medical records retrospectively. A diagnosis of dementia was
made according to DSM IV, that is, when the patient had both
memory disturbance and any other disturbances in language,
calculation, execution, and praxis ability. Additional information
(age, sex, age of PD onset, onset symptoms [tremor-dominant or
not], family history of PD [ﬁrst- or second-degree relatives], psy-
chosis history [hallucination and delirium], current or previous
impulse control disorder, mood disorders [deﬁned as prescribing
of antidepressants or antianxiety agents], history of stereotactic
surgery for PD, and onset-year of dementia, psychosis [halluci-
nation or delirium], wearing-off, dyskinesia) was collected from
the clinical records. When information was insufﬁcient, the in-
vestigators interviewed the patients or their caregivers. If not
obtained, the subjects were excluded from the analyses and their
numbers were shown. Dopaminergic medications (e.g., daily L-
dopa dose, dopamine agonists, selegiline, amantadine, and enta-
capone) on the day of enrollment were recorded. The levodopa
equivalent dose was calculated with the formula for levodopa
equivalent doses for antiparkinsonian drugs described in a sys-
tematic review by Tomlinson et al. (2010). Early and late heart/
mediastinum (H/M) ratios on 123I- MIBG myocardial scintigraphy,
and IMP-SPECT at Utano National Hospital were collected together
with the examination date.
2.7. Statistics
2.7.1. Relative risk of PD related to GBA mutations
The relative risk of PD related to GD-associated GBA mutations
and other GBA mutations was estimated separately as odds ratios
(ORs) in the analyses between PD patients and healthy controls, and
statistical signiﬁcance was examined by Fisher’s exact tests. If no
mutations were observed in a cell, OR was calculated after a 0 cell
correction (0.5 was added to all cells), because of the inability to
divide it by a 0 cell count.
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mutation groups
Collected clinical features at enrollment were compared be-
tween the PD patients with GD-associated GBA mutations, with
mutations unreported in GD and without mutations. The categor-
ical data were examined by Fisher’s exact tests, and the scale data
were examined by Student t tests (after Levene’s test to determine
equality of variances) or ManneWhitney U-tests (non-Gaussian
distributions).
2.7.3. Survival time analyses in motor and nonmotor features by
GBA-mutation groups
KaplaneMeier survival curves were obtained from retrospective
cohort analyses to compare time-to-event between patients with
and without mutations, and the statistical differences were exam-
ined by a log-rank test. The survival time was deﬁned as the
duration from PD onset to the development of wearing-off, dyski-
nesia, dementia, and psychosis, for up to 12 years. Hazard ratios
(HRs) of GBAmutations for these symptoms were calculated in Cox
proportional-hazard regression models adjusted for sex and age at
PD onset.
p-Values of <0.05 were considered statistically signiﬁcant. The
statistical analyses were performed with the statistical software
program IBM SPSS Statistics version 19.0 (IBM Corporation,
Armonk, NY, USA).Table 1
Frequency of glucocerebrosidase gene allele in Parkinson’s disease patients and
controls
Allele name PD
(n ¼ 215)
Controls
(n ¼ 126)
p Odds ratio
(95% CI)
GD-associated mutations
R120W 7a 0 0.050 9.1 (0.5e160.8)
RecNciI (L444P-A456P-
V460)
4 0
L444P 4 0
D409H 1 0
A384D 1 0
D380N 1 0
444L(1447-1466 del 20,
insTG)
1 0
b2.8. N-isopropyl-p[123I] iodoamphetamine single-photon emission
tomography imaging and analysis
A dose of 111 MBq 123I-IMP was injected (supine position, quiet
surroundings, and eye closed), and scanning was done for
15e30 minutes after injection. Using a gamma camera (Symbia E
Dual Head System, SIEMENS) and an analytical workstation
(syngo MI Workplace V, SIEMENS), the projection data were ob-
tained in a 128  128 format for 36 angles in 180 increments at a
rate of 30 seconds per angle. To elucidate the relatively decreased
IMP uptake, a semiquantitative analytic approach originally
developed for positron-emission tomography images by
Minoshima et al. (1995) was adapted to single-photon emission
tomography (SPECT) imaging (Bartenstein et al., 1997; Hirsch
et al., 1997). After global normalization to the mean cerebral
blood ﬂow (CBF) for the entire brain, pixel-by-pixel comparisons
of rCBF were performed to elucidate the CBF reduction patterns of
subjects with GD-associated mutations versus subjects without
mutations (matched by sex, age 5 years, and disease duration
5 years). T-statistic values (converted Z) were calculated be-
tween both groups at each pixel and displayed by color-coding
representation onto the imaged brain anatomy. Image analysis
was performed using software NEUROSTAT iSSP version 3.5, 2tZ
(developed by Minoshima et al., University of Washington, Seat-
tle, USA).Subtotal, n (%) 19 (8.8%) 0 (0%) <0.001 25.1 (1.5e419.8)
Nonsynonymous mutations not reported in GD
I(-20)V 27a 13 0.603 1.3 (0.6e2.5)
I489V 3 0
Y11Hc 0 1
Subtotal, n (%) 30 (14.0%) 14 (11.1%) 0.506 1.3 (0.7e2.6)
Synonymous, n
K466K 2a 1
L336L 1a 0
Allele names refer to the processed protein (excluding the 39-residue signal pep-
tide).
Key: CI, conﬁdence interval; GD, Gaucher disease; PD, Parkinson’s disease.
a Four subjects had double mutations; 2 of I(-20)V and K466K, 1 of I(-20)V and
R120W, and 1 of R120W and L336L.
b Odds ratio was calculated by adding 0.5 to each value.
c Novel mutation.3. Results
3.1. Subjects
Among the 224 eligible PD patients (the subjects were not
related to each other), 9 subjects were excluded from the analysis (4
due to multiple system atrophy ﬁndings on subsequent brain MRI
and 5 because of insufﬁcient clinical information). Therefore, 215
PD patients [female, 52.1%; age, 66.7  10.8 (mean  standard de-
viation)] were analyzed. For non-PD healthy controls, 126 patients’
spouses (female, 58.7%; age, 67.3 10.3) without a family history of
PD or GD were enrolled.3.2. GBA mutations and risk ratios for PD
In the PD subjects, we identiﬁed 10 nonsynonymous and 2
synonymous GBA variants. Within the nonsynonymous variants, 7
mutations were previously reported in GD [R120W, L444P-A456P-
V460 (RecNciI), L444P, D409H, A384D, D380N, and 444L(1447-1466
del 20, insTG)] as GD-associated mutations. Three nonsynonymous
mutations have never been reported in GD patients [I(-20)V, I489V,
and there was one novel mutation (Y11H)].
GD-associated GBAmutations were found in 19 of the 215 (8.8%)
PD patients but none in the healthy controls. The risk of PD
development relative to these GD-associated mutations was esti-
mated as an OR of 25.1 [95% conﬁdence interval (CI), 1.50e420,
p ¼ 0.0001] with 0-cell correction. The nonsynonymous mutations
that were not reported in GD patients had no association with PD
development (p ¼ 0.506; OR, 1.3; 95% CI, 0.7e2.6) (Table 1). Four
subjects had double mutations. For subsequent analyses, 2 subjects
with double mutations of I (-20)V and K466K were adopted to the
group of mutations unreported in GD, and 2 subjects with double
mutations of R120W and I(-20)V, and of R120W and L336L were
adopted to the group of GD-associated mutations.3.3. Clinical features of PD patients by GBA mutation groups
The clinical features of PD patients with GD-associated muta-
tions, those with mutations unreported in GD, and those without
mutations are shown in Table 2. In the GD-associated mutation
group, females, those with a family history and those with de-
mentia (DSM IV) were signiﬁcantly more frequent than those in the
no-mutation group (p ¼ 0.047, 0.012, and 0.020, respectively). The
age of PD onset was lower in patients with GD-associated muta-
tions (55.2  9.9 years  standard deviation), compared with those
without mutations (59.3  11.5), although the statistical difference
was not signiﬁcant. There were no differences in clinical manifes-
tations between subjects with mutations unreported in GD and
Table 2
Epidemiological and clinical features of PD patients with Gaucher diseaseeassociated GBA mutations, those with mutations previously unreported in GD and those without
mutations
Variables Total n ¼ 215 Mutation (-) GD-associated mutations Mutations unreported in GD
167 19a pb 29c pd
Sex Female, n (%) 83 (49.7) 14 (73.7) 0.047 15 (51.7) ns
Age Mean (SD) 67.0 (10.8) 62.2 (10.7) 0.063e 67.5 (11.2) nsf
Disease duration (y) Mean (SD) 7.7 (5.5) 6.9 (4.6) nsf 7.2 (4.9) nsf
Onset age Mean (SD) 59.3 (11.5) 55.2 (9.9) ns 60.3 (11.8) ns
Family history Yes, n (%) 17 (11.0)g 6 (31.6) 0.012 0 (0.0) ns
Dementia (DSM-IV) Yes, n (%) 29 (17.4) 9 (47.4) 0.020 5 (17.2) ns
MMSE Mean (SD) 25.8 (5.4)h 23.3 (7.7) nsf 27.0 (3.4)i nsf
Onset symptom (tremor vs. others) Tremor, n (%) 78 (46.8) 9 (47.4) ns 15 (51.7) ns
Modiﬁed H-Y on (<3 vs. 3) 3, n (%) 82 (49.1) 14 (73.7) 0.042 16 (55.2) ns
UPDRS part 3 Mean (SD) 23.6 (12.2)j 28.5 (13.8) nsf 21.9 (8.7) nsf
Wearing off Yes, n (%) 70 (41.9) 9 (47.4) ns 13 (44.8) ns
Dyskinesia Yes, n (%) 49 (29.3) 8 (42.1) ns 8 (27.6) ns
Mood disorder Yes, n (%) 43 (25.7) 8 (42.1) ns 7 (24.1) ns
Orthostatic hypotension symptom Yes, n (%) 21 (12.6) 5 (26.3) ns 7 (24.1) ns
Psychosis history Yes, n (%) 59 (35.3) 10 (52.6) ns 7 (24.1) ns
ICD history Yes, n (%) 8 (4.8) 1 (5.3) ns 1 (3.4) ns
Stereotactic brain surgery for PD Yes, n (%) 4 (2.4) 0 (0.0) ns 0 (0.0) ns
Agonist LED mg/d Mean (SD) 92.8 (114.2) 72.1 (137.7) nse 163.7 (155.6) 0.026e
Levodopa LED mg/d Mean (SD) 400.7 (184.2) 456.7 (206.9) nsf 369.2 (230.3) nse
Total LED mg/d Mean (SD) 496.4 (233.7) 537.9 (258.9) nsf 525.7 (287.4) nsf
Categorical data were examined by Fisher’s exact test.
Key: DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; GBA, glucocerebrosidase gene; GD, Gaucher disease; H-Y, Hoehn and Yahr; ICD, impulse
control disorder; LED, levodopa equivalent dose; ns, not signiﬁcant; MMSE, Mini-Mental State Examination; PD, Parkinson’s disease; SD, standard deviation; UPDRS, Uniﬁed
Parkinson’s Disease Rating Scale.
a Including a double-mutation subject (with a mutation unreported in GD).
b GD-associated mutations versus mutation (-).
c Two subjects with double mutation, including GD-associated mutations, were assigned to GD-associated mutation group.
d Other mutations versus mutation (-).
e Examined by Student t test after Levene’s test for equality of variances.
f Examined by Mann-Whitney U-test because of non-Gaussian distribution.
g n ¼ 155 due to 10 missing data.
h n ¼ 164 due to 3 missing data.
i n ¼ 28 due to 1 missing datum.
j n ¼ 165 due to 2 missing data.
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(p ¼ 0.026) (Table 2).3.4. Survival time analyses to develop dementia, psychosis,
dyskinesia, and wearing-off
Time to develop clinical outcomes (dementia, psychosis, dyski-
nesia, and wearing-off) was compared in 19 subjects with GD-
associated mutations, 29 with mutations unreported in GD, and 167
without mutation. The median observation time was 6.0 years. The
subjectswithGD-associatedmutations showed a signiﬁcantly earlier
development of dementia and psychosis, compared with subjects
without mutation (p < 0.001 and p ¼ 0.017) (Supplementary
Table e-1, Fig. 1A and B). We rereviewed the clinical record of the
subjectwho showedearlydementia (deﬁnedbyDSMIV) (Fig.1A) and
made sure it did not satisfy the criteria of DLB (McKeith et al., 2005).
The associations of GBA mutations and these symptoms were
estimated as HRs, adjusting for sex and age at PD onset. HRs were
8.3 for dementia (95% CI, 3.3e20.9; p < 0.001) and 3.1 for psychosis
(95% CI, 1.5e6.4; p ¼ 0.002). The time until development of
wearing-off and dyskinesia complications was not statistically sig-
niﬁcant, with HRs of 1.5 (95% CI, 0.8e3.1; p ¼ 0.219) and 1.9 (95% CI,
0.9e4.1; p ¼ 0.086) (Table 3).
Subjects with mutations unreported in GD did not show sig-
niﬁcant differences in time to develop all 4 outcomes, compared
with no mutation subjects. Therefore, subjects with GD-unreported
mutations were regarded as subjects without GBA mutations in
further analyses.3.5. rCBF on SPECT in patients with GD-associated GBA mutations
We conducted pixel-by-pixel comparisons of rCBF on SPECT
between PD subjects with mutations (cases) and sex-, age-, and
disease duration-matched PD subjects without any mutations in
GBA (controls). Four controls were adopted for each case (except for
a 34-year-old female case who was matched to a control), and in
total 12 cases (female 50%, age at SPECT mean  standard error
(SE); 58.9  3.3 years, disease duration at SPECT 7.3  1.5 years)
and 45 controls (female 64.4%, age at SPECT mean  SE; 61.0 
1.3 years, disease duration at SPECT 7.1  0.7 years) were analyzed.
As a result, a signiﬁcantly lower rCBF was seen in the cases
compared to the controls in the bilateral parietal cortex, including
the precuneus (Fig. 2).
3.6. H/M ratios on MIBG scintigraphy in patients with GD-
associated GBA mutations
Cardiac MIBG scintigraphy visualizes catecholaminergic termi-
nals in vivo that are reduced as well as brain dopaminergic neurons
in PD patients. We also investigated MIBG scintigraphy between 16
cases (female 68.8%, age at examination mean  SE; 60.2 
2.6 years, disease duration at examination 6.2  1.2 years) and sex-,
age- and disease duration-matched 61 controls [(63.8 %, age 62.0 
1.1 years, disease duration 5.5  0.6 years) (1:4 except for 1 young
34-year-old female case who was matched to a control)]. In the
results, both early and late H/M ratios declined in both groups and
did not show any signiﬁcant differences (p ¼ 0.309 and 0.244)
(Supplementary Table e-2).
Fig. 1. KaplaneMeier curves of dementia and psychosis in Parkinson’s disease (PD) patients with Gaucher disease (GD)-associated glucocerebrosidase gene (GBA) mutations and
those without mutations. PD patients with GD-associated GBA mutations and those without GBA mutations were compared to investigate the time taken to develop dementia (A)
and psychosis (B). Because of insufﬁcient information in several patients, the numbers in each analysis were different. The patients with and without mutations were 17 and 165 (A),
18 and 165 (B) against a total of 19 and 167. DSM IV, Diagnostic and Statistical Manual of Mental Disorders, revised fourth edition. p-Values were calculated by log-rank tests.
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4.1. Contributions of GD-associated GBA mutations to the
development of PD
In the analysis of 215 PD patients and 126 non-PD controls, we
identiﬁed 10 nonsynonymous heterozygous GBA mutations,
including 1 novel mutation. Among these mutations, 7 were
GD-associated, and the patients carrying these mutations repre-
sented 8.8% of the PD cohort. No signiﬁcant association was found
between the GD-unreported mutations and PD development,
which suggests that only the GD-associated mutations are a ge-
netic risk for PD. According to a worldwide multicenter analysis of
1883 fully sequenced PD patients, 7% of the GD-associated muta-
tions are found in non-Ashkenazi Jewish PD patients (Sidransky
et al., 2009). Although the mutation frequency in the present
study was similar to previous results, the OR of GD-associated
heterozygous mutations (25.1) was signiﬁcantly greater than the
OR (5.43) of other ethnic cohorts (Sidransky et al., 2009) and was
consistent with an OR of 28.0 from a previous Japanese report
(Mitsui et al., 2009). These results, taken together, suggest the
possibility that GBA mutations are at a distinct risk for PD in the
Japanese population. However, a larger Japanese cohort study is
required to conﬁrm this.4.2. Cross-sectional clinical ﬁgures of PD with GBA mutations
Before the survival time analyses, we investigated clinical fea-
tures at enrollment between mutation groups. The lower onset age,
more frequent family history and dementia, and worse disease
severity of PD in patients with GBAmutations, compared with those
without mutations, were consistent with previous cross-sectional
case-control reports (Anheim et al., 2012; Brockmann et al., 2011;
Chahine et al., 2013; Lesage et al., 2011; Li et al., 2013; MitsuiTable 3
Hazard ratios of GBA pathogenic mutations for clinical symptoms
Model Clinical feature Hazard ratio 95% CI p
1 Dementia (DSM-IV) 8.3 3.3e20.9 <0.001
2 Psychosis 3.1 1.5e6.4 0.002
3 Wearing-off 1.5 0.8e3.1 0.219
4 Dyskinesia 1.9 0.9e4.1 0.086
Each model was adjusted for sex and age at onset.
Key: CI, conﬁdence interval; DSM-IV; The Diagnostic and Statistical Manual of
Mental Disorders part 1IV; GBA, glucocerebrosidase.et al., 2009; Neumann et al., 2009; Seto-Salvia et al., 2012;
Sidransky et al., 2009). In contrast, female-predominance (73.7%,
p¼ 0.047) in patients withmutations observed in the present study
is inconsistent (Neumann et al., 2009; Seto-Salvia et al., 2012).
4.3. Impact of GBA mutations on the clinical course of PD
To investigate the impact of GBA mutations on the clinical
course of PD, a prospective-designed study over a long period is
preferred. Although there has been a few longitudinally designed
study to date, follow-up clinical data for a median of 6 years of 121
PD cases from a community-based incident cohort was recently
reanalyzed; results demonstrate that progression to dementia
deﬁned by DSM IV (HR 5.7) and Hoehn and Yahr stage 3 (HR 3.2)
are signiﬁcantly earlier in 4 GBA mutation-carrier patients
compared with 117 patients with wild-type GBA (Winder-Rhodes
et al., 2013). A 2-year follow-up clinical report of 28 heterozy-
gous GBA carriers who were recruited from relatives of GD-
patients shows slight but signiﬁcant deterioration of cognition
and smelling, compared to healthy controls (Beavan et al., 2015).
Brockmann et al. (2015) assessed motor and nonmotor symptoms
including cognitive and mood disturbances for 3 years in 20 PD
patients with GBA mutations and showed a more rapid disease
progression of motor impairment and cognitive decline in GBA
mutation cases comparing to sporadic PD controls. The current
long-term retrospective cohort study up to 12 years reinforced
these results. It revealed that dementia and psychosis developed
signiﬁcantly earlier in subjects with GD-associated mutations
compared with those without mutation, and the HRs of GBA mu-
tations were estimated at 8.3 for dementia and 23.1 for psychosis,
with adjustments for sex and PD onset age. In contrast, the results
showed no signiﬁcant difference in developing wearing-off and
dyskinesia.
In this study, we also investigated whether GD-unreported
mutations affected the clinical course of PD. In both cross-
sectional and survival time analyses, the mutations unreported in
GD carried no increased burden on clinical symptoms such as de-
mentia, psychosis, wearing-off, and dyskinesia.
4.4. Reduced rCBF in PD with GBA mutations compared with
matched PD controls
We found a signiﬁcantly decreased rCBF, reﬂecting decreased
synaptic activity, in the bilateral parietal cortex including the pre-
cuneus, in subjects with GD-associated mutations compared with
Fig. 2. Regional cerebral blood ﬂow in the group with GD-associated mutations compared with the matched Parkinson’s disease group without mutations. Regions with lower
regional cerebral blood ﬂow in the group with GD-associated mutations displayed on an anatomic reference map. Abbreviation: GD, Gaucher disease.
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was very similar to the pattern of H215O positron-emission tomog-
raphy that Goker-Alpan et.al. (2012) reported, showing decreased
resting rCBF in the lateral parietal association cortex and the pre-
cuneus bilaterally in GD subjects with parkinsonism (7 subjects
with homozygous or compound heterozygous GBA mutations),
compared with 11 PD without GBA mutations. Results suggest that
PD with heterozygous GBA mutations and GD patients presenting
parkinsonism had a common reduced pattern of rCBF. Interestingly,
in their study, rCBF in the precuneusdbut not in the lateral parietal
cortexdcorrelated with IQ, suggesting that the involvement of the
precuneus is critical for deﬁning GBA-associated patterns.
4.5. Reduced cardiac MIBG H/M ratios as well as matched PD
controls
We also showed that cardiac MIBG H/M ratios in subjects with
GD-associated mutations were lower than the cutoff point for PD
discrimination (Sawada et al., 2009), suggesting that postganglionic
sympathetic nerve terminals to the epicardiumwere denervated, as
well as in PD without mutations.
4.6. Mechanisms of impact on PD clinical course by GD-associated
GBA mutations
Experimental studies suggesting a bidirectional pathogenic loop
between a-synuclein and glucocerebrosidase have been accumulated
(Fishbein et al., 2014; Gegg et al., 2012; Mazzulli et al., 2011; Noelker
et al., 2015; Schondorf et al., 2014; Uemura et al., 2015). Loss of glu-
cocerebrosidase function compromises a-synuclein degradation in
lysosome, whereas aggregated a-synuclein inhibits normal lysosomal
function of glucocerebrosidase. The pathogenic loop may facilitate
neurodegeneration in GD-associated PD brain, resulting in early
development of dementia or psychosis as shown in the present study.
Several recent researches propose the possibility that the similar
mechanism as in PD with GBAmutations exists even in idiopathic PD
brain (Alcalay et al., 2015; Chiasserini et al., 2015; Gegg et al., 2012;
Murphy et al., 2014). On the other hand, the impacts of
GD-associated GBA mutations for the development of motor compli-
cations such as wearing-off and dyskinesia were not statistically sig-
niﬁcant, suggesting other pathophysiological mechanisms in the
striatal circuitbroughtoutafter long-termtherapyespeciallyby L-dopa.
4.7. Limitations
Our study has several limitations. In the design of the study, we
assumed that the sample size was 215 (PD patients) for survival time
analyses and investigated 224 PD patients. We assumed that the
mutationprevalencewould be 9.4%, and in fact, we found 19 patientswithmutations (8.5%) of the 224 patients. Based on these ﬁgures, we
estimated the risk ratios of heterozygous GBA mutations for the risk
of PD development and PD clinical symptoms as ORs in the cross-
sectional multivariate analyses, although the 95% CIs were broad.
More of subject numbers will be needed to determine robust risk
ratios. For cross-sectional analyses, as for comparisons of the CBF
imaging studies the number was insufﬁcient. For that reason, we
compared the images of the positive patients to those of age-, sex-
and disease duration-matched PD controls. Another limitation of the
study concerns its nature as a retrospective cohort study; Although
we determined the onset time of dementia, psychosis, wearing-off,
and dyskinesia from clinical records or interview from both pa-
tients and their caregivers, we had to exclude several subjects from
analysis because of insufﬁcient information about onset-year (the
missing numbers are shown in Supplementary Table e-1).5. Conclusions
In conclusion, we showed that GD-associated mutations were
not only associated with the development of PD but also had a great
impact on developing dementia and psychosis in the clinical course
of PD. The rCBF analysis in this study suggests that the dysfunction
of the bilateral parietal cortex, including the precuneus, may play a
role, although we have towait for other investigations to determine
the molecular mechanism. In terms of the development of motor
complications, the GD-associated mutations did not show a sig-
niﬁcant inﬂuence.Disclosure statement
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